NH SB455

Requires health insurance carriers in New Hampshire to cover GLP-1 medications (such as Ozempic, Wegovy) for individuals with a BMI of 40 or higher

Mandates coverage for individuals with a BMI of 35 or higher who have at least one qualifying comorbidity: Type 2 diabetes, hypertension, coronary artery disease, sleep apnea, high cholesterol/hyperlipidemia, or severe osteoarthritis

Amends RSA 420-J (Managed Care Law) by adding new section 420-J:6-f

Takes effect 60 days after passage

Fiscal impact includes an indeterminable increase in state General Fund revenue from higher insurance premium taxes, with potential increased expenditures of $100-200 million statewide based on induced demand of 10-20 percent; does not apply to self-funded plans like the State Employee Health Benefit Plan